HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
Stocks · News reference
CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — CervoMed Inc. (CRVO)
Filed: 2026-08-10 AccNo: 0001437749-26-026771 Size: 207 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.
CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.60) by 6.67 percent. This is a 8.57 percent increase over losses of $(0.70) per share from the